



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

To,

Date: 13.02.2021

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting

Ref: Scrip Code 538965

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Saturday, 13.02.2021 at 5:00 p.m. at the registered office of the company the following were considered and approved:

1. Un-Audited financial results for the quarter ended 31.12.2020. **(Enclosed)**
2. Limited Review Report as per Regulation 33 of SEBI (LODR) Regulations, 2015 for the quarter ended 31.12.2020. **(Enclosed)**
3. Appointment of Mr. NagavenkataHareesh Kumar Solleti as Non-Executive Independent director the company

Disclosure as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 with regard to appointment as mentioned above is enclosed hereunder.

The meeting concluded at 6:00 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Concord Drugs Limited

S. N. Reddy
NAGI REDDY SEELAM
Whole-time Director
DIN: 01764665



Encl: as above



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

Disclosure as per Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 with regard to appointment or resignations as mentioned above is enclosed hereunder.

Sl. no	Particulars	Mr. NagavenkataHareesh Kumar Solleti
1	Reason for change viz appointment, resignation	Appointed as Non-Executive Independent Director of the company
2	Date of appointment	13.02.2021
3	Term of Appointment	Upto Annual General Meeting
4	Brief profile	Mr. NagavenkataHareesh Kumar Solleti is a Bcom Graduate and has a experience 8 years in pharmasector.
5	Relationship with other directors	Mr. Hareesh Kumar is not related to the existing directors or promoters
6	Share holding	Mr. NagavenkataHareesh Kumar Solleti is not holding any shares in the company



S. N. R.



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST December 2020

[Rs. in Lakhs]

Particulars	Quarterly ended			Nine Months Ended		Year ended
	31-Dec-20 (UnAudited)	30-Sep-20 (UnAudited)	31-Dec-19 (UnAudited)	31-Dec-20 (UnAudited)	30-Dec-19 (UnAudited)	31-Mar-20 (Audited)
I Revenue from Operations						
a. Net sales from Operations	824.073	1,656.67	1,090.56	4,301.07	3,831.06	5,133.89
b. Other Operating Income	0.666	4.49	2.45	7.31	7.46	12.01
II Other Income						
III Total Revenue (I+II)	824.74	1,661.16	1,092.71	4,308.38	3,838.52	5,145.89
IV Expenses						
a. Cost of Material Consumed	614.422	1,384.38	876.25	3,496.37	3,089.20	4,206.02
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	2.659	26.73	1.29	126.11	72.37	51.72
c. Employees Benefit Expenses	95.166	101.09	89.59	283.26	265.93	350.72
d. Finance Costs	21.736	48.90	40.10	114.54	127.41	154.37
e. Depreciation and Amortisation expense	38.745	33.04	36.89	103.52	110.11	146.39
f. Other expenses	46.675	56.12	44.82	145.99	140.45	191.03
Total Expenses	819.40	1,650.26	1,086.35	4,269.79	3,805.47	5,100.25
Profit/ (Loss) before Exceptional item and tax (III-IV)	5.3	10.90	6.36	38.6	33.05	45.65
V Exceptional Items	352.3	-	-	352.3	-	-
VI Profit/ (Loss) before tax (V+VI)	357.67	10.90	6.36	390.92	33.05	45.65
VII Tax Expense:	87.83	2.83	1.93	96.48	9.54	12.82
VIII a. Current tax	39.770	1.69	1.65	46.91	8.88	11.91
b. Deferred tax charge/credit	48.062	1.15	0.28	49.56	0.66	0.91
IX Profit/ (Loss) for the period (VII-VIII+V)	269.841	8.07	4.43	294.45	23.51	32.83
X Other Comprehensive Income						
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	269.84	8.07	4.43	294.45	23.51	32.83
XI Paid-up equity share capital (Face value of the share- Rs. 10 each)	874.38	874.38	874.38	874.38	874.38	874.38
XII Earnings per share (of Rs. 10 each)						
XIII a. Basic (in Rs)	3.09	0.09	0.05	3.37	0.27	0.38
b. Diluted (in Rs)	3.09	0.09	0.05	3.37	0.27	0.38

Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 13th february, 2021
- The company adopted the Indian Accounting standards (Ind AS) from 01.04.2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India.
Note: The figures for the qtrr ended March 31, 2020 are balancing figures between the Audited figures of the full financial year ended 31, March 2020 & the published year to date figures upto 9 months ended Dec 31, 2020
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- The results are also available on the website of the Company www.concorddrugs.in

By Order of the Board
For Concord Drugs Limited

Managing Director

DIN: 01764665



Place: Hyderabad


Date: 13-02-2021



Independent Auditor's Review Report on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 31 December 2020, and the year to date results for the period 1 April 2020 to 31 December 2020, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For N G Rao and Associates
Chartered Accountants
FRN: 009399S**




(CA G Nageswara Rao)

Partner

M No: 207300

UDIN No: 21207300AAAAMx4872

Place: Hyderabad

Date: 13-02-2021